AI Summary
Summary: The number of patients with chronic fatigue syndrome (ME/CFS) is anticipated to increase due to the long-term impacts of the COVID-19 pandemic. Scientists have discovered potential biomarkers to enhance the diagnosis and treatment of persistent and disabling fatigue.
The number of ME/CFS patients is expected to rise drastically due to long-term effects of the COVID-19 pandemic. Scientists have now identified possible biomarkers that could improve the diagnosis and treatment of long-lasting and debilitating fatigue.